Endoter

Company Overview

Snapshot

Founded in September 2025, Endoter operates with 1–10 employees. The company is currently in its Pre-Funding stage, focusing on the development of non-opioid pain relief solutions.

Business overview

Endoter (EndorTech) is an Israeli healthtech startup specializing in the development of synthetic biological beta-endorphin formulations delivered via aerosol. The company's core technology aims to provide potent, targeted pain relief as a natural alternative to opioid painkillers, with a focus on reducing side effects and offering competitive costs. Endoter serves the healthcare market, specifically targeting clinical settings where conventional opioid-based therapies are currently used, operating within the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics.

Company Intelligence Q&A

What is Endoter's primary focus?

Endoter's primary focus is developing synthetic beta-endorphin aerosols for non-opioid pain relief, aiming to replace conventional opioid-based therapies.

When was Endoter founded?

Endoter was founded in September 2025.

In which sector does Endoter primarily operate?

Endoter primarily operates in the Health Tech & Life Sciences sector, with a specific focus on Medical Devices and Medical Treatment & Therapeutics.

What is the current employee size of Endoter?

Endoter currently has 1–10 employees.

What is Endoter's current product development stage?

Endoter is currently in the R&D stage for its synthetic beta-endorphin aerosol product.